Neonatal screening for congenital hypothyroidism in Mexico: Experience, obstacles, and strategies

Journal of Medical Screening

Volumn 6, Issue 2, 1999, Pages 77-79

  Vela, Marcela ^a   Gamboa, Salvador ^a   Loera Luna, Antonio ^a   Aguirre, Blanca Estela ^a   Pérez Palacios, Gregorio ^a,d   Velázquez, Antonio ^b,c,e  

^a SECRETARÍA DE SALUD   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^d Reproductive Health Agency ^*

^e Nutritional Genetics Unit

Author keywords

Congenital hypothyroidism; Neonatal screening; Thyroid stimulating hormone

Indexed keywords

THYROTROPIN;

ARTICLE; CONGENITAL HYPOTHYROIDISM; COST BENEFIT ANALYSIS; ENZYME IMMUNOASSAY; FEMALE; GOITER; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MEXICO; NEWBORN; NEWBORN SCREENING; THYROTROPIN BLOOD LEVEL; UMBILICAL CORD BLOOD;

EID: 0033021824     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1136/jms.6.2.77     Document Type: Article

References (14)

1. Velázquez A. Neonatal screening in countries with socioeconomic developmental problems: results of an international inquiry. In: Farriaux J-P, Dhondt J-L, eds. New horizons in neonatal screening. New York: Elsevier, 1994:301-3.
2. Villarreal ML, Galindo LM, Velázquez A. Newborn genetic screening: the Mexican program. In: Lisker R, Armendares S, eds. Human genetics. Amsterdam: Excerpta Medica, 1977:214-24.
3. Rodríguez M, Martínez G, Velázquez A. Neonatal metabolic screening in developing countries: the case of Mexico. In: Therrell BLJ, ed. Advances in neonatal screening. Austin: Elsevier, 1987:461-6.
4. Carrasco C, Ruíz de CháVez S, Rodríguez-Budelli M, et al. Cost-benefit analysis of the Mexican neonatal screening program for inborn errors of metabolism. In: Therrell BLJ, ed. Advances in neonatal screening. Amsterdam: Excerpta Medica, 1987:447-8.
5. Poder-Ejecutivo-Federal. Norma técnica No 321 para la prevención del retraso mental producido por hipotiroidismo congénito. México: diario oficial de la federación. Vol 14. Mexico: Gobierno Constitucional de los Estados Unidos Mexicanos, 1988:88-90.
6. Velázquez A, Loera A, Aguirre BE, et al. Resultados del programa mexicano de tamiz neonatal para hipotiroidismo congénito y fenilcetonuria. Salud Publica Mex 1994;36: 249-56.
7. Loera-Luna A, Aguirre BE, Gamboa S, et al. Resultados del programa para la prevención del retraso mental producido por hipotiroidismo congénito. Boletín Médico del Hospital Infantil de México 1996;53:259-63.
8. Jewell SE, Slazyk WJ, Smith SJ, et al. Sources of imprecision in laboratories screening for congenital hypothyroidism: analysis of nine years of performance data. Clin Chem 1989;35:1701-5.
9. Klett M. Epidemiology of congenital hypothyroidism. Exp Clin Endocrinol Diabetes 1997;105(suppl 4):19-23.
10. Toublanc J-E. New horizons in neonatal screening. In: Farriaux J-P, Dhondt J-L, eds. 2nd Meeting of the International Society for Neonatal Screening. Lille, France: Excerpta Medica, 1993:149-53.
11. Lorey FW, Cunningham GC. Birth prevalence of primary congenital hypothyroidism by sex and ethnicity. Hum Biol 1992;64:531-8.
12. Therrell BL, Meyer D, Brown LO, et al. Incidence of primary congenital hypothyroidism in Texas by race and sex. National newborn screening symposium, Chicago. Chicago, IL: Illinois Department of Health, 1982:57-60.
13. Fisher DA, Klein AH. Thyroid development and disorders of thyroid function in the newborn. N Engl J Med 1981;304:702-12.
14. Sweetman L. Newborn screening by tandem mass spectrometry. Clin Chem 1996;42:345-6.